Confirmation of MNGC reduction in 1α,25(OH)₂D₃-pretreated A549 cells during <i>B</i>. <i>pseudomallei</i> infection. by Pohnratchada Mattrasongkram (14593528)

Bedload composition, transport and modification in rivers of Westland, New Zealand, with implications for the distribution of alluvial pounamu (jade) by SC Cox (740448)

“…<div><p>River bedload surveyed at 50 sites in Westland is dominated by Alpine Schist or Torlesse Greywacke from the Alpine Fault hanging wall, with subordinate Pounamu Ultramafics or footwall-derived Western Province rocks. …”

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Cell cycle progression is impaired in <i>radA</i> plants. by Nicolas Chevigny (12537052)

Fig 2 - by Nazlı Tunar Özcan (14833635)

Optogenetic stimulation of the hippocampal CA1 astrocytes does not significantly affect the expression of AMPA receptors or VGLUT2. by Jae-Hong Kim (124622)

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Distribution of traffic accidents by age, gender, and seat belt use. by Bayapa Reddy Narapureddy (11875358)

Distribution of Facial bone fractures associated with other body structures injuries. by Bayapa Reddy Narapureddy (11875358)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Facial traumas considering seat belt use in victims. by Bayapa Reddy Narapureddy (11875358)

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Traffic accident victims by position in the vehicle, gender, and safety equipment. by Bayapa Reddy Narapureddy (11875358)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)